Salvage Radiation Therapy Plus Enzalutamide for High-Risk Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
J. Clin. Oncol 2022 Nov 11;[EPub Ahead of Print], PT Tran, K Lowe, HL Tsai, DY Song, AY Hung, JWD Hearn, S Miller, JA Proudfoot, MP Deek, R Phillips, T Lotan, CJ Paller, CH Marshall, M Markowski, S Dipasquale, S Denmeade, M Carducci, M Eisenberger, TL DeWeese, M Orton, C Deville, E Davicioni, SL Liauw, EI Heath, S Greco, NB Desai, DE Spratt, F Feng, H Wang, TM Beer, ES AntonarakisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.